Danaè Williams

DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM).

E. Terpos, S. Usmani, G. Ferron-Brady, 2020 .

DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma

S. Usmani, C. Min, B. Kremer, 2021, Blood.

Demographic diversity of US-based participants in GSK-sponsored interventional clinical trials

Ouzama Henry, S. McCallister, S. Sampson, 2023, Clinical trials.